Ryoncil is part of a development programme for inflammatory diseases such as SR-aGvHD in adults, and biologic-res

Mesoblast (ASX:MSB) has received approval from the US Food and Drug Administration (FDA) for Ryoncil (remestemcel-L), making it the first mesenchymal stromal cell (MSC) therapy to be approved in the United States for any indication.

More than four years later—and after two rejections from the agency—Mesoblast has finally gained an endorsement from the U.S. regulator for its first approved drug.